iifl-logo

Suven Pharmaceuticals Ltd Board Meeting

1,019.5
(-1.57%)
Jul 25, 2025|12:00:00 AM

Suven Pharma CORPORATE ACTIONS

26/07/2024calendar-icon
26/07/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting26 Jun 202526 Jun 2025
Disclosure under Regulation 30 of the SEBI Listing Regulations
Board Meeting28 May 202526 Mar 2025
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve the financial results for the period ended March 31 2025 Financial Results for period ended March 31, 2025 (As Per BSE Announcement Dated on :28.05.2025)
Board Meeting25 Apr 202525 Apr 2025
Intimation of Effective Date of merger and Record Date
Board Meeting12 Feb 202527 Dec 2024
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ending December 31 2024 Outcome of the Board Meeting (As Per BSE Announcement Dated on 12/02/2025)
Board Meeting12 Nov 202426 Sep 2024
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ending September 30 2024 Outcome of the Board Meeting (As per BSE Announcement Dated on 12/11/2024)
Board Meeting19 Sep 202419 Sep 2024
Change in Directorate
Board Meeting9 Aug 20242 Aug 2024
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Friday the 09th August 2024 at 01:00 p.m. IST at the Corporate Office 202 A-Wing Galaxy Towers Plot No.1 Hyderabad Knowledge City TSIIC Raidurg Hyderabad Telangana - 500081 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the first quarter ended June 30 2024 and other matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July 2024 as per PIT Code of the Company. Trading window will be opened from 12th August 2024. Outcome of the Board Meeting Appointment of Company Secretary and Compliance Officer effective from September 03, 2024 (As per BSE Announcement Dated on 09/08/2024)

Suven Pharma: Related News

Suven Pharma Q3 Profit Jumps 77% YoY, Revenue Up 40%
13 Feb 2025|03:10 PM

Revenue from operations of the company stood at ₹307.2 crore, with a Year-on-Year (YoY) growth of 39.8% quarter over Q3 FY24 as compared to ₹219.8 crore

Read More
Suven Pharma picks up controlling stake in NJ Bio for ₹535 Crore
9 Dec 2024|07:23 AM

Suven is now a prominent player in the ADC outsourcing market, estimated to be worth $2.7 billion (approx. ₹22,815 Crore).

Read More
Top 10 stocks for today – 12th August 2024
12 Aug 2024|08:48 AM

Here are some of the stocks that may see significant price movement today: Adani Enterprises, Siemens, Aurobindo Pharma, etc.

Read More
Top 10 stocks for today – 15th July, 2024
15 Jul 2024|08:59 AM

Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.